{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:44:26Z","timestamp":1786164266991,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>BMD loss is common after denosumab discontinuation, and longer treatment is associated with greater BMD loss. Serum crosslaps (sCTX) can predict BMD loss at the lumbar spine after discontinuation. Keeping sCTX below the lower half of the ULN during the first year is needed to avoid BMD loss at 2 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>After denosumab discontinuation (DD), elevated serum crosslaps (sCTX) is associated with bone mineral density (BMD) loss over 2 years. Bisphosphonates reduce but do not always prevent this loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To define an sCTX threshold below which BMD is maintained after DD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Postmenopausal women receiving\u2009\u2265\u20092 denosumab doses and followed\u2009\u2265\u20092\u00a0years after DD with regular BMD and sCTX measurements were included retrospectively. Linear regression analysis and ROC curves were performed to define sCTX threshold (%ULN, upper limit of the norm in premenopausal women) preventing 1- and 2-year lumbar spine (LS) BMD loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 161 women who had received 8.0\u2009\u00b1\u20092.9 injections, 50% lost BMD after 2\u00a0years. BMD at DD were similar at all sites in non-losers and losers\u2019 groups but losers had received more injections. Their T-score decreased after 1 and 2\u00a0years (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). BMD loss was highly correlated with increased sCTX during both periods. After DD, first-year sCTX levels predicted 1- and 2-year LS BMD loss. The optimal sCTX thresholds during the first year to avoid LS BMD loss at 1 and 2\u00a0years were 69% and 49% ULN; for 100% sensitivity, they were 32% and 23% ULN, respectively. Losers received more often\u2009\u2265\u20093 zoledronate infusions and were less treated with alendronate only.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sCTX level during the first year after DD predict 1- and 2-year LS BMD loss. Keeping sCTX below the lower half of the ULN during the first year is needed to avoid BMD loss. Despite high bisphosphonates doses, it is not always possible to reach this target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01747-0","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:29:17Z","timestamp":1786163357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Keeping bone resorption markers very low for 1 year after denosumab prevents bone loss at 2 years: the ReoLaus study"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8636-4524","authenticated-orcid":false,"given":"Giovanni","family":"Liebich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"Olivier","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-2988","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6008","authenticated-orcid":false,"given":"Elena","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,8]]},"reference":[{"key":"1747_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48:677\u2013692. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"key":"1747_CR2","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"},{"key":"1747_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5:513\u2013523. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1747_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"1747_CR5","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1530\/EJE-16-1027","volume":"176","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Yavropoulou MP, Makras P et al (2017) Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol 176:677\u2013683. https:\/\/doi.org\/10.1530\/EJE-16-1027","journal-title":"Eur J Endocrinol"},{"key":"1747_CR6","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald MM, Khoo WH, Ng PY et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184:1330-1347.e13. https:\/\/doi.org\/10.1016\/j.cell.2021.02.002","journal-title":"Cell"},{"key":"1747_CR7","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96:972\u2013980. https:\/\/doi.org\/10.1210\/jc.2010-1502","journal-title":"J Clin Endocrinol Metab"},{"key":"1747_CR8","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","volume":"27","author":"B Aubry-Rozier","year":"2016","unstructured":"Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O (2016) Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. Osteoporos Int 27:1923\u20131925. https:\/\/doi.org\/10.1007\/s00198-015-3380-y","journal-title":"Osteoporos Int"},{"key":"1747_CR9","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P et al (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases: DENOSUMAB DISCONTINUATION AND VERTEBRAL FRACTURES. J Bone Miner Res 32:1291\u20131296. https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Miner Res"},{"key":"1747_CR10","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD et al (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28:1723\u20131732. https:\/\/doi.org\/10.1007\/s00198-017-3919-1","journal-title":"Osteoporos Int"},{"key":"1747_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","volume":"29","author":"MB Zanchetta","year":"2018","unstructured":"Zanchetta MB, Boailchuk J, Massari F et al (2018) Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int 29:41\u201347. https:\/\/doi.org\/10.1007\/s00198-017-4242-6","journal-title":"Osteoporos Int"},{"key":"1747_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2020","unstructured":"Burckhardt P, Faouzi M, Buclin T et al (2020) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36:1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Miner Res"},{"key":"1747_CR13","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2020","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2020) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Miner Res 37:2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Miner Res"},{"key":"1747_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D et al (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102:354\u2013358. https:\/\/doi.org\/10.1210\/jc.2016-3170","journal-title":"J Clin Endocrinol Metab"},{"key":"1747_CR15","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","volume":"179","author":"E Gonzalez-Rodriguez","year":"2020","unstructured":"Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D et al (2020) Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 179:153\u2013159. https:\/\/doi.org\/10.1007\/s10549-019-05458-8","journal-title":"Breast Cancer Res Treat"},{"key":"1747_CR16","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K (2016) Rebound-associated vertebral fractures after discontinuation of denosumab\u2014from clinic and biomechanics. Osteoporos Int 27:1917\u20131921. https:\/\/doi.org\/10.1007\/s00198-015-3458-6","journal-title":"Osteoporos Int"},{"key":"1747_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116498","volume":"163","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2022) Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting. Bone 163:116498. https:\/\/doi.org\/10.1016\/j.bone.2022.116498","journal-title":"Bone"},{"key":"1747_CR18","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"key":"1747_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"1747_CR20","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Miner Res"},{"key":"1747_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","volume":"21","author":"AS S\u00f8lling","year":"2023","unstructured":"S\u00f8lling AS, Tsourdi E, Harsl\u00f8f T, Langdahl BL (2023) Denosumab discontinuation. Curr Osteoporos Rep 21:95\u2013103. https:\/\/doi.org\/10.1007\/s11914-022-00771-6","journal-title":"Curr Osteoporos Rep"},{"key":"1747_CR22","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA et al (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34:2220\u20132228. https:\/\/doi.org\/10.1002\/jbmr.3853","journal-title":"J Bone Miner Res"},{"key":"1747_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116764","volume":"172","author":"G Liebich","year":"2023","unstructured":"Liebich G, Lamy O, Aubry-Rozier B, Gonzalez-Rodriguez E (2023) Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study. Bone 172:116764. https:\/\/doi.org\/10.1016\/j.bone.2023.116764","journal-title":"Bone"},{"key":"1747_CR24","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae224","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M et al (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion? J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae224","journal-title":"J Clin Endocrinol Metab"},{"key":"1747_CR25","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR et al (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35:1207\u20131215. https:\/\/doi.org\/10.1002\/jbmr.3962","journal-title":"J Bone Miner Res"},{"key":"1747_CR26","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1007\/s00198-017-4108-y","volume":"28","author":"T Lehmann","year":"2017","unstructured":"Lehmann T, Aeberli D (2017) Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int 28:3067\u20133068. https:\/\/doi.org\/10.1007\/s00198-017-4108-y","journal-title":"Osteoporos Int"},{"key":"1747_CR27","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36:1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Miner Res"},{"key":"1747_CR28","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE et al (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162. https:\/\/doi.org\/10.1210\/clinem\/dgab321","journal-title":"J Clin Endocrinol Metab"},{"key":"1747_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115830","volume":"144","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830. https:\/\/doi.org\/10.1016\/j.bone.2020.115830","journal-title":"Bone"},{"key":"1747_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae044","volume":"8","author":"V Farias","year":"2024","unstructured":"Farias V, Jerkovich F, Barrag\u00e1n AM et al (2024) Three-year effect of bisphosphonates on bone mineral density after denosumab withdrawal: observations from a real-world study. JBMR Plus 8:ziae044. https:\/\/doi.org\/10.1093\/jbmrpl\/ziae044","journal-title":"JBMR Plus"},{"key":"1747_CR31","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530\u2013537. https:\/\/doi.org\/10.1002\/jbmr.251","journal-title":"J Bone Miner Res"},{"key":"1747_CR32","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.bone.2007.01.008","volume":"40","author":"AE De Papp","year":"2007","unstructured":"De Papp AE, Bone HG, Caulfield MP et al (2007) A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 40:1222\u20131230. https:\/\/doi.org\/10.1016\/j.bone.2007.01.008","journal-title":"Bone"},{"key":"1747_CR33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG (2019) Stopping denosumab. Curr Osteoporos Rep 17:8\u201315. https:\/\/doi.org\/10.1007\/s11914-019-00502-4","journal-title":"Curr Osteoporos Rep"},{"key":"1747_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s40520-025-02991-z","volume":"37","author":"O Lamy","year":"2025","unstructured":"Lamy O, Everts-Graber J, Rodriguez EG (2025) Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. Aging Clin Exp Res 37:70. https:\/\/doi.org\/10.1007\/s40520-025-02991-z","journal-title":"Aging Clin Exp Res"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01747-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01747-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01747-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T04:29:18Z","timestamp":1786163358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01747-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1747"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01747-0","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,8]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}